MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.
about
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Notch signaling deregulation in multiple myeloma: A rational molecular targetThe Link between Autoimmunity and Lymphoma: Does NOTCH Signaling Play a Contributing Role?Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth.Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsAnti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application.Notch signaling and cardiac repair.γ-Secretase Inhibitor Alleviates Acute Airway Inflammation of Allergic Asthma in Mice by Downregulating Th17 Cell Differentiation.Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.Overexpression of the Notch3 receptor and its ligand Jagged1 in human clinically non-functioning pituitary adenomasNotch 2 signaling contributes to cell growth, anti-apoptosis and metastasis in laryngeal squamous cell carcinomaMultifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.Molecularly targeted therapies in multiple myelomaThe challenge of targeting notch in hematologic malignancies.Pleiotropic roles of Notch signaling in normal, malignant, and developmental hematopoiesis in the human.The osteoblastic niche in the context of multiple myeloma.Signaling Pathways and Emerging Therapies in Multiple Myeloma.Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.Notch signaling drives multiple myeloma induced osteoclastogenesis.Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation.Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.Perspectives on the discovery of NOTCH2-specific inhibitors.PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells.Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma
P2860
Q26785497-044BA2C3-3BB0-451D-A178-8915BCCB9272Q26797283-726BFAA7-0E04-4CC8-B43E-F60D0B616140Q28082490-6ADC1EBD-2D92-4670-BB54-16919BABFE6FQ30434130-C24F9526-01F6-4F2B-A30C-03B10936A364Q33851035-5F4C6A3E-E62A-4C3D-9B92-0C2DF5BE975DQ33875590-D9DB0AAC-FAC7-406A-A772-9A65D833D766Q34038854-219CF3BE-874F-4A47-86C2-CE53A37B47FDQ34490880-DD40EFA4-7E13-41EF-984C-F0289D7156E9Q34712645-070FD822-4EDE-4382-A3DE-FA880664ACD2Q35946564-0E397F9A-C05B-4876-8B2A-FAE5703EBB77Q35962890-4B2F116F-551B-4DFA-BAC4-3C2670DC5CA3Q36301590-B868C285-8C60-4F8C-81BE-6117F727ADEEQ36621195-8554477B-574A-451C-A3BF-6E6FEB4C47F9Q37297583-0FAAB99C-F7A8-4FA8-BBB3-3023F64855D5Q37460101-0F8AFDA4-1FEA-4104-A2EB-7F9566FC0E84Q37636618-65DD65CD-06EA-4B23-BCD1-B628BC604F14Q38211866-5608A2E6-84D0-4EAE-AF4C-A368C5A450A5Q38222770-80FCCCD5-F2C7-4DA0-8FE3-D998E62119BEQ38253998-0A9A6BF8-81A8-4F5A-A9FE-030F4DF72D11Q38271428-8F2F41FE-4D9E-4F0C-B15D-718C58305374Q38753307-A863A2D8-39CC-48DA-8A1C-F4DC0D99C419Q38950582-B02827F2-F6B7-4348-B1A8-B3C68EB9F509Q38953233-B9549043-8072-46E0-9392-AFCAA2AC9D40Q38953409-BC9DDCE5-1C7D-4EF4-A68C-174662DAC9CCQ39120190-1AD0F7E1-2686-4174-A57A-C827268F625AQ41770950-401113AF-3C43-4ABB-BC98-A4874870A0F8Q48113221-26CFD047-5FC3-4D3D-AAF9-EFBD9FBD4318Q48263465-CCB14CAF-2726-4386-9C6B-9BF79502C526Q51045630-8EF249CE-1889-475C-BFF2-3E1137F41126Q57818334-6E04F45C-3A48-446D-9EC9-0EF524DD28E3
P2860
MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
MRK003, a γ-secretase inhibito ...... ma and non-Hodgkin's lymphoma.
@ast
MRK003, a γ-secretase inhibito ...... ma and non-Hodgkin's lymphoma.
@en
type
label
MRK003, a γ-secretase inhibito ...... ma and non-Hodgkin's lymphoma.
@ast
MRK003, a γ-secretase inhibito ...... ma and non-Hodgkin's lymphoma.
@en
prefLabel
MRK003, a γ-secretase inhibito ...... ma and non-Hodgkin's lymphoma.
@ast
MRK003, a γ-secretase inhibito ...... ma and non-Hodgkin's lymphoma.
@en
P2093
P2860
P356
P1433
P1476
MRK003, a γ-secretase inhibito ...... oma and non-Hodgkin's lymphoma
@en
P2093
T Kimlinger
V Ramakrishnan
P2860
P2888
P304
P356
10.1038/LEU.2011.192
P577
2011-08-09T00:00:00Z